Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy

References

• Singh B, Carpenter G, and Coffey RJ. EGF receptor ligands: recent advances. F1000Research, 2016. 5.
   Google Scholar
• Yu XT, Zhu SN, Xu ZD, et al. Roles of EGFR-Stat3 signal pathway in carcinogenesis of experimental hepatoma in rats. J Cancer Res Clin Oncol. 2007;133(3):145–152.
   PubMed Web of Science ®Google Scholar
• Conesa-Zamora P, Torres-Moreno D, Isaac MA, et al. Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cell-cycle markers and HPV presence. Exp Mol Pathol. 2013;95(2):151–155.
   PubMed Web of Science ®Google Scholar
• Frederick L, Wang XY, Eley G, et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000;60(5):1383–1387.
   PubMed Web of Science ®Google Scholar
• Anido J, Scaltriti M, Bech Serra JJ, et al. Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translation. EMBO J. 2006;25(13):3234–3244.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12(18):5268–5272.
   PubMed Web of Science ®Google Scholar
• Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21(2):177–184.
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors—impact on future treatment strategies. Nat Rev Clin Oncol. 2010;7(9):493–507.
   PubMed Web of Science ®Google Scholar
• Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest. 2008;118(11):3574–3581.
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7(10):2958–2970.
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy—the fourth annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture. Clin Cancer Res. 2000;6(3):747–753.
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J clin oncol. 2003;21(14):2787–2799.
   PubMed Web of Science ®Google Scholar
• Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J clin oncol. 2005;23(11):2445–2459.
   PubMed Web of Science ®Google Scholar
• Galizia G, Lieto E, De Vita F, et al. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene. 2007;26(25):3654–3660.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–578.
   PubMed Web of Science ®Google Scholar
• Ng M, Cunningham D. Cetuximab (Erbitux)–an emerging targeted therapy for epidermal growth factor receptor‐expressing tumours. Int J Clin Pract. 2004;58(10):970–976.
   PubMed Web of Science ®Google Scholar
• Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16(9):1425–1433.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–345.
   PubMed Web of Science ®Google Scholar
• Busam K, Capodieci P, Motzer R, et al. Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol. 2001;144(6):1169–1176.
   PubMed Web of Science ®Google Scholar
• Hollywood E. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225. In: Seminars in oncology nursing. Elsevier; 2002;May;18(2 Suppl 2):30-5.
   Google Scholar
• Liu S, Gao W, Wang Y, et al. Comprehensive N-glycan profiling of cetuximab biosimilar candidate by NP-HPLC and MALDI-MS. PloS One. 2017;12(1):e0170013.
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1, 3-galactose. N Engl J Med. 2008;358(11):1109–1117.
   PubMed Web of Science ®Google Scholar
• van Bueren JJL, Rispens T, Verploegen S, et al. Anti-galactose-α-1, 3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol. 2011;29(7):574–576.
   PubMed Web of Science ®Google Scholar
• Jacquenet S, Moneret-Vautrin D-A, Bihain BE. Mammalian meat–induced anaphylaxis: clinical relevance of anti–galactose-α-1, 3-galactose IgE confirmed by means of skin tests to cetuximab. J Allergy Clin Immunol. 2009;124(3):603–605.
   PubMed Web of Science ®Google Scholar
• Mangla A, Agarwal N. Relevance of Anti–Galactose-α-1, 3-Galactose antibodies in the era of monoclonal antibodies. J Oncol Pract. 2019;15(12):679–680.
   PubMed Web of Science ®Google Scholar
• Qian J, Liu T, Yang L, et al. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole–quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem. 2007;364(1):8–18.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation of human IgG antibodies: relevance to therapeutic applications. Recent research developments in immunology. 2002: 769–780
   Google Scholar
• Janin-Bussat MC, Tonini L, Huillet C, et al. Cetuximab Fab and Fc N-glycan fast characterization using IdeS digestion and liquid chromatography coupled to electrospray ionization mass spectrometry. Methods Mol Biol. 2013;988:93–113.
   PubMedGoogle Scholar
• Kimura H, Sakai K, Arao T, et al. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 2007;98(8):1275–1280.
   PubMed Web of Science ®Google Scholar
• Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs. 1999;17(3):259–269.
   PubMed Web of Science ®Google Scholar
• Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 2000;6(6):2166–2174.
   PubMed Web of Science ®Google Scholar
• Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000;6(2):701–708.
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res. 1999;5(4):909–916.
   PubMed Web of Science ®Google Scholar
• Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res. 2000;6(12):4874–4884.
   PubMed Web of Science ®Google Scholar
• Patel D, Bassi R, Hooper A, et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int J Oncol. 2009;34(1):25–32.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Bonucci C, et al. Experimental HER2-targeted therapies for biliary tract cancer. Expert Opin Investig Drugs. 2021;30(4):389–399.
   PubMed Web of Science ®Google Scholar
• Perrotte P, Harbison MT, Davis DW, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 1999;5(2):257–265.
   PubMed Web of Science ®Google Scholar
• Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 2000;6(5):1936–1948.
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs. 2002;11(6):755–768.
   PubMed Web of Science ®Google Scholar
• Graham J, Muhsin M, and Kirkpatrick P. Cetuximab. Nat Rev Drug Discov. 2004;3(7):549-551.
   Web of Science ®Google Scholar
• Cohen MH, Chen H, Shord S, et al. Approval summary: cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Oncologist. 2013;18(4):460.
   PubMed Web of Science ®Google Scholar
• Keating GM. Panitumumab. Drugs. 2010;70(8):1059–1078.
   PubMed Web of Science ®Google Scholar
• Giusti RM, Shastri KA, Cohen MH, et al. FDA drug approval summary: panitumumab (Vectibix™). Oncologist. 2007;12(5):577–583.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Necitumumab: first global approval. Drugs. 2016;76(2):283–289.
   PubMed Web of Science ®Google Scholar
• Fala L. Portrazza (Necitumumab), an IgG1 monoclonal antibody, FDA approved for advanced squamous non–small-cell lung cancer. Am Health Drug Benefits. 2016;9:119. Spec Feature.
   PubMedGoogle Scholar
• Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. In: MAbs. Taylor & Francis; 2009;1(1):41-48.
   Google Scholar
• Tabasinezhad M, Omidinia E, Talebkhan Y, et al. The effects of somatic mutations on EGFR interaction with anti‐EGFR monoclonal antibodies: implication for acquired resistance. Proteins Struct Funct Bioinf. 2020;88(1):3–14.
   PubMed Web of Science ®Google Scholar
• Voigt M, Braig F, Göthel M, et al. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia. 2012;14(11):1023–IN3.
   PubMed Web of Science ®Google Scholar
• Bagchi A, Haidar JN, Eastman SW, et al. Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance. Mol Cancer Ther. 2018;17(2):521–531.
   PubMed Web of Science ®Google Scholar
• Taberna M, Oliva M, Mesía R. Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma. Front Oncol. 2019;9:383.
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Tabernero J. Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. Curr Opin Invest Drugs. 2010;11(12):1434–1441.
   PubMed Web of Science ®Google Scholar
• Mazorra Z, Chao L, Lavastida A, Nimotuzumab: beyond the EGFR signaling cascade inhibition. Semin Oncol. 2018 Jan;45(1-2):18-26.
   Web of Science ®Google Scholar
• García-Foncillas J, Sunakawa Y, Aderka D, et al. Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors. Front Oncol. 2019;9:849.
   PubMed Web of Science ®Google Scholar
• López-Albaitero A, Ferris RL. Immune activation by epidermal growth factor receptor–specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngology Head Neck Surg. 2007;133(12):1277–1281.
   PubMedGoogle Scholar
• Cai W-Q, Zeng L-S, Wang L-F, et al. The latest battles between EGFR monoclonal antibodies and resistant tumor cells. Front Oncol. 2020;10:1249.
   PubMed Web of Science ®Google Scholar
• Lee SC, Srivastava RM, López-Albaitero A, et al. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res. 2011;50(2–3):248–254.
   PubMed Web of Science ®Google Scholar
• Lattanzio L, Denaro N, Vivenza D, et al. Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy. Cancer Immunol Immunother. 2017;66(5):573–579.
   PubMed Web of Science ®Google Scholar
• Hou M, Ho CL, Lin HY, et al. A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck. Ann Oncol. 2019;30:ix26–ix27.
   Google Scholar
• Petrelli F, Ardito R, Ghidini A, et al. Different toxicity of cetuximab and panitumumab in metastatic colorectal cancer treatment: a systematic review and meta-analysis. Oncology. 2018;94(4):191–199.
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. 2008 Apr 1;26(10):1626-34.
   Google Scholar
• Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. 2008 Dec 10;26(35):5705-5712.
   Google Scholar
• Van Cutsem E, Köhne C-H, Láng I, et al. Cetuximab plus Irinotecan, Fluorouracil, and Leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–2019.
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–762.
   PubMed Web of Science ®Google Scholar
• Montagut C, Dalmases A, Bellosillo B, et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012;18(2):221–223.
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011;3(99):99ra86–99ra86.
   PubMed Web of Science ®Google Scholar
• Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1(6):508–523.
   PubMed Web of Science ®Google Scholar
• Zhang L, Castanaro C, Luan B, et al. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. Mol Cancer Ther. 2014;13(5):1345–1355.
   PubMed Web of Science ®Google Scholar
• Wang D, Qian G, Zhang H, et al. HER3 targeting sensitizes HNSCC to cetuximab by reducing HER3 activity and HER2/HER3 dimerization: evidence from cell line and patient-derived xenograft models. Clin Cancer Res. 2017;23(3):677–686.
   PubMed Web of Science ®Google Scholar
• Novoplansky O, Fury M, Prasad M, et al. MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. Int J Cancer. 2019;145(3):748–762.
   PubMed Web of Science ®Google Scholar
• Tan C-S, Kumarakulasinghe NB, Huang Y-Q, et al. Third generation EGFR TKIs: current data and future directions. Mol Cancer. 2018;17(1):1–14.
   PubMedGoogle Scholar
• Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–Positive lung cancer and acquired resistance to Osimertinib. JAMA Oncol. 2018;4(11):1527–1534.
   PubMed Web of Science ®Google Scholar
• Helena AY, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-Mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247.
   PubMed Web of Science ®Google Scholar
• Grabe T, Lategahn J, and Rauh D. C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?. ACS Med Chem Lett 2018;9(8):779-782.
   Web of Science ®Google Scholar
• Haura EB, Cho BC, Lee JS, JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC), J Clin Oncol. 2019;37(15_suppl):9009-9009.
   Google Scholar
• Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Mol Cancer Ther. 2020;19(10):2044–2056.
   PubMed Web of Science ®Google Scholar
• Huang S, van Duijnhoven SM, Sijts AJ, et al. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. J Cancer Res Clin Oncol. 2020;146:3111–3122.
   Web of Science ®Google Scholar
• Huehls AM, Coupet TA, Sentman CL. Bispecific T‐cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93(3):290–296.
   PubMed Web of Science ®Google Scholar
• Panchal A, Seto P, Wall R, et al. COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors. MAbs. Taylor & Francis; 2020;12(1):1792130.
   Google Scholar
• Mandrup OA, Ong SC, Lykkemark S, et al. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity. Commun Biol. 2021;4(1):1–11.
   PubMed Web of Science ®Google Scholar
• Phillips AC, Boghaert ER, Vaidya KS, et al. ABT-414, an antibody–drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther. 2016;15(4):661–669.
   PubMed Web of Science ®Google Scholar
• He K, Xu J, Liang J, et al. Discovery of A novel EGFR-Targeting antibody–drug conjugate, SHR-A1307, for the treatment of solid tumors resistant or refractory to anti-EGFR therapies. Mol Cancer Ther. 2019;18(6):1104–1114.
   PubMed Web of Science ®Google Scholar